Stelara ustekinumab: Additional Phase III data

Additional data from the double-blind Phase III PHOENIX 1 trial in 766 patients showed that maintenance dosing with 45 and 90 mg Stelara every 12 weeks produced PASI 75 responses of 64% and 76%, respectively, at 3 years. Additionally, >70% of patients who were responders at week 40 and continued maintenance dosing with Stelara every 12 weeks achieved significant improvements in skin diseases-specific quality of life as measured by a >=5 point improvement in the DLQI at 3 years. Data were presented at the European Academy of Dermatology and Venereology meeting in Gothenburg. ...